


<b>Name</b>	Amornpun Wongkarnjana, MD, MSc	
<b>Country</b>	Thailand	
<b>Organization</b>	King Chulalongkorn Memorial Hospital Chulalongkorn University	
<b>Current Position</b>	Faculty and Program Co-director of Pulmonary Fellowship Training at Division of Pulmonary and Critical Care Medicine, Department of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University	

### Educational Background

- Bachelor degree of Medicine (MD) from Chulalongkorn University, Thailand, in 2008
- Diploma of Thai Board of Internal Medicine by The Medical Council of Thailand, in 2014
- Diploma of Thai Board of Pulmonary Medicine and Pulmonary Critical Care by The Medical Council of Thailand, in 2016
- Master degree of Science (MSc) from Chulalongkorn University, Thailand, in 2016
- Certificate of Respiratory Clinical Fellowship in Interstitial Lung Disease from McMaster University, Canada, in 2020

### Professional Experiences

- Respiratory clinical fellowship in interstitial lung disease at McMaster University from April 1<sup>st</sup>, 2018 to May 30<sup>th</sup>, 2020. I worked with Prof. Martin Kolb at ILD and combined Respiratory-Rheumatology clinic at Firestone Institute for Respiratory Health (FIRH), St Joseph Healthcare Hamilton, Canada.
- Speaker for ILD sessions at The Annual Conference of Thoracic Society of Thailand under Royal Patronage (TST) from 2020 – 2023
- Speaker for medical events organized by Boehringer Ingelheim Company
- Speaker for a sponsored symposium at the 26<sup>th</sup> Congress of the Asia Pacific Society of Respiriology, hold on 18<sup>th</sup> November 2022 in South Korea, under the topic “Evidence-based approach in early treatment for IPF”

### Professional Organizations

Member of

- Royal College of Physicians Thailand (RCPT)
- Assembly of interstitial lung disease, occupational and environmental lung disease; Thoracic Society of Thailand under Royal Patronage (TST)
- Asia Pacific Society of Respiriology
- American Thoracic Society (ATS)
- European respiratory society

---

### Main Scientific Publications

---

- **Wongkarnjana A**, Yanagihara T, Kolb M. (2019)  
Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update. *Expert Rev Respir Med.* 2019 Dec;13(12):1139-1146. doi: 10.1080/17476348.2019.1673733. Epub 2019 Oct 9.
  - **Wongkarnjana A**, Ryerson C. (2020)  
Progressive fibrosing interstitial lung disease: we know it behaves badly, but what does that mean? *Eur Respir J.* 2020 Jun 25;55(6):2000894. doi: 10.1183/13993003.00894-2020.
  - **Wongkarnjana A**, Scallan C, Kolb M. (2020)  
Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies. *Curr Opin Pulm Med.* 2020 Sep;26(5):436-442. doi: 10.1097/MCP.0000000000000712.
  - **Wongkarnjana A**, Kawkitinarong K and Uaprasert N.  
Association of biochemical determinants and fibrinous formation in malignant pleural effusion.  
Poster presentation at ERS International Congress 2016, London, United Kingdom.
  - Alsilmi R, **Wongkarnjana A**, Scallan CJ, Haider E, Al-Douri F, Zou H, Beattie K, Granholm MA, Kolb M, Khalidi NA, Hambly N, Makhdami N, Nair P, Cox G (2019)  
Factors Associated With Disease Progression In Patients With Myeloperoxidase-Antineutrophil Cytoplasmic Antibody-Related Pulmonary Fibrosis.  
Poster presentation at the 19th International Vasculitis and ANCA Workshop, Philadelphia, Pennsylvania, USA.
  - Author of McMaster Textbook of Internal Medicine. Kraków: Medycyna Praktyczna.  
(<https://empendium.com/mcmtxtbook/>)  
Chapters: Bronchiolitis obliterans, Pleural effusion, Pneumomediastinum, Pneumothorax, Subcutaneous emphysema
-